Page last updated: 2024-10-15
ammeline
Description
ammeline: causes retinal degeneration [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 135408770 |
| CHEBI ID | 28646 |
| SCHEMBL ID | 36982 |
| MeSH ID | M0040093 |
Synonyms (62)
| Synonym |
|---|
| CHEBI:28646 |
| 4,6-diamino-1,3,5-triazin-2-ol |
| s-triazin-2-ol, 4,6-diamino- |
| 1,3,5-triazin-2(1h)-one, 4,6-diamino- |
| s-triazin-2-ol,6-diamino- |
| nsc9778 |
| 2,3,5-triazin-6-one |
| nsc-9778 |
| 1,5-triazin-2(1h)-one, 4,6-diamino- |
| ammelin |
| 2-hydroxy-4,6-diamino-1,3,5-triazine |
| ammeline |
| C08733 |
| 645-92-1 |
| 2,4-diamino-1,3,5-triazin-6-one |
| A0676 |
| 2,4-diamino-6-hydroxy-1,3,5-triazine |
| 3,4,5,6-tetrahydro-4,6-diimino-1,3,5-triazin-2(1h)-one |
| cyanurodiamide |
| 2,6-diamino-1h-1,3,5-triazin-4-one |
| 2,6-bis(azanyl)-1h-1,3,5-triazin-4-one |
| A834820 |
| AKOS006223976 |
| ammeline (van) |
| ammelin (van) |
| unii-lc8g9556q0 |
| einecs 211-455-1 |
| 4,6-diamino-1,3,5-triazin-2(1h)-one |
| ai3-50983 |
| lc8g9556q0 , |
| nsc 9778 |
| FT-0622303 |
| AKOS015894773 |
| diaminohydroxytriazine |
| cyanurdiamide |
| atrazine-desethyl-desisopropyl-2-hydroxy |
| 4,6-diamino-2-hydroxy-1,3,5-triazine |
| ammeline-13c3 |
| 6am , |
| SCHEMBL36982 |
| 4,6-diamino-1,3,5-triazin-2(5h)-one |
| DTXSID3060950 , |
| ammeline, (4,6-diamino-5-triazin-2-ol) |
| ammeline, |
| mfcd00023186 |
| AKOS027383197 |
| atrazine-desethyl-desisopropyl-2-hydroxy, pestanal(r), analytical standard |
| 6-amino-5-azacytosine |
| 4,6-diamino-5h-1,3,5-triazine-2-one |
| ammeline; desethylisopropylhyroxyatrazine |
| ammeline = 2,4-diamino-6-hydroxy-s-triazine |
| Q4747227 |
| 2,4-diamino-1,3,5-triazine-6-one |
| D88306 |
| AS-56019 |
| SB83877 |
| azacitidine impurity 10 (metformin impurity pound(c) |
| CS-0164694 |
| cid 5281298 |
| 4,6-diamino-1h-1,3,5-triazin-2-one |
| EN300-4282413 |
| diamino-1,3,5-triazin-2-ol |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (2)
| Class | Description |
|---|---|
| monohydroxy-1,3,5-triazine | |
| diamino-1,3,5-triazine | Any member of the class of 1,3,5-triazines that consists of a 1,3,5-triazine skeleton substituted by two amino groups. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (24)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (4.17) | 18.7374 |
| 1990's | 1 (4.17) | 18.2507 |
| 2000's | 2 (8.33) | 29.6817 |
| 2010's | 19 (79.17) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 24 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||